APO-DICLO RAPIDE 50 MG TABLETS 50 MG
DICLOFENAC POTASSIUM : 50 MG · DIN 02243433 · APOTEX INC
Health Canada status: CANCELLED POST MARKET
What is APO-DICLO RAPIDE 50 MG TABLETS?
APO-DICLO RAPIDE 50 MG TABLETS 50 MG contains DICLOFENAC POTASSIUM : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02243433, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 21-Jul-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-DICLO RAPIDE 50 MG TABLETS used for?
Short-term (up to one week) treatment of acute, mild to moderately severe pain and inflammation (e.g., sprains, post-operative dental pain, episiotomy, or dysmenorrhea).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02243433 |
|---|---|
| Brand name | APO-DICLO RAPIDE 50 MG TABLETS |
| Generic / active ingredient | DICLOFENAC POTASSIUM : 50 MG |
| Manufacturer | APOTEX INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AB05 DICLOFENAC |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 21-Jul-2024 |
| Original market date | 2001-03-14 00:00:00 |
How is it administered?
Use lowest effective dose for shortest possible duration. Indicated for short-term (up to one week) treatment of acute pain. Not to be used concomitantly with diclofenac sodium.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (mentions 'Storage and Stability' section on page 24, but content is not in snippet).
How is it supplied?
Not explicitly detailed in provided text (mentions 'Dosage Forms, Composition and Packaging' section on page 24, but content is not in snippet).
Contraindications
CABG surgery peri-operative setting; third trimester of pregnancy; breastfeeding; severe heart failure; hypersensitivity to diclofenac or NSAIDs; active GI ulcer/bleeding; inflammatory bowel disease.
Warnings and precautions
Increased risk of serious cardiovascular thrombotic events (MI, stroke); serious gastrointestinal events (bleeding, ulceration, perforation); hepatotoxicity; hypertension; fluid retention.
Is DICLOFENAC in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by PHARMA STULLN INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code M01AB05 DICLOFENAC. 15 of 74 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DICLO | 25 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 00839175 |
| APO-DICLO | 50 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 00839183 |
| APO-DICLO SR | 100 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02091194 |
| APO-DICLO SR | 75 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02162814 |
| CAMBIA | 50 MG | POWDER FOR SOLUTION | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 02381680 |
| PMS-DICLOFENAC | 25 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02302616 |
| PMS-DICLOFENAC | 50 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02302624 |
| PRO-DICLOFENAC | 50 MG | TABLET (DELAYED-RELEASE) | PRO DOC LIMITEE | MARKETED | DIN 00870978 |
| SANDOZ DICLOFENAC RAPIDE | 50 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02261774 |
| SANDOZ-DICLOFENAC | 50 MG | SUPPOSITORY | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02261928 |
Who else supplies DICLOFENAC worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DICLOFENAC appears in 17208 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.